Sign in / Join Now
ETFs & Funds
announced initial results from a Phase I multicenter safety study of
-001 in treatment-resistant Crohn's Disease.
Add a reply...
Latest StockTalks »
people get CELG breaking news and analysis by email alert.
Get email alerts on CELG »
Get latest price
From other sites
Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects
at TheStreet (Wed, 5:20PM)
NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day
at Zacks.com (Wed, 9:30AM)
Celgene vs. Regeneron: Which Stock is a Better Pick?
at Zacks.com (Tue, 9:28AM)
Nearly 350 Abstracts Evaluating Celgene Therapies To Be Presented At American Society Of Hematology Annual Meeting (ASH)
at TheStreet (Nov 22, 2016)
Celgene Corporation To Webcast An Analyst And Investor Event From The American Society Of Hematology Meeting In December
at TheStreet (Nov 21, 2016)